• Alcon

    Alcon yesterday announced the launch of Ilevero (nepafenac ophthalmic suspension) 0.3%, a once-daily, non-steroidal anti-inflammatory drug (NSAID) for the treatment of pain and inflammation associated with cataract surgery.

    The drug demonstrated superior clinical efficacy compared to vehicle in two double-masked, randomized clinical trials. By day 14, inflammation (65 percent vs. 32 percent) and pain (86 percent vs. 46 percent) resolved in more Ilevero-treated patients. 

    The most frequently reported adverse reactions following cataract surgery were capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure, and sticky sensation, which occurred in 5 to 10 percent of patients.